A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy

被引：0
|
作者：
DeWeese, T
Arterbery, E
Michalski, J
Sylvester, JE
Terris, MK
Wilding, G
Yu, DC
Moore, L
Kimball, L
Ando, D
Kim, D
机构：
[1] Johns Hopkins Oncol Ctr, Baltimore, MD USA
[2] Wayne State Univ, Rochester, MI USA
[3] Washington Univ, Med Ctr, St Louis, MO USA
[4] Seattle Prostate Inst, Seattle, WA USA
[5] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[6] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[7] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[8] Cell Genesys Inc, Foster City, CA USA
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1158
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 35 条
  • [31] Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb):: a pilot phase I/II trial
    Pöttgen, C
    Eberhardt, W
    Bildat, S
    Stüben, G
    Stamatis, G
    Hillejan, L
    Sohrab, S
    Teschler, H
    Seeber, S
    Sack, H
    Stuschke, M
    ANNALS OF ONCOLOGY, 2002, 13 (03) : 403 - 411
  • [32] Toxicity and Patient Reported Quality of Life after PSMAPET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial
    Spohnfr, S. K. B.
    Gainey, M.
    Kamps, M.
    Jilg, C. A.
    Gratzke, C.
    Sigle, A.
    Mix, M.
    Ruf, J.
    Buerkle, S.
    Sprave, T.
    Wiehle, R.
    Serpa, M.
    Benndorf, M.
    Zschaeck, S.
    Ghadjar, P.
    Baltas, D.
    Kirste, S.
    Zamboglou, C.
    Grosu, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S95 - S95
  • [33] Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Whang, Young E.
    Kaur, Gurveen
    Vallabhajosula, Shankar
    Christos, Paul J.
    Nikolopoulou, Anastasia
    Jhanwar, Yuliya
    Sheikh, Arif
    Ireland, Adam
    Garcias-Espana, Carmen
    Goldsmith, Stanley J.
    Beltran, Himisha
    Bander, Neil Harrison
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Akhtar, Naveed H.
    Osborne, Joseph
    Beltran, Himisha
    Saran, Ankeeta
    Mileo, Gina
    Ecker, Caryn
    Goldsmith, Stanley J.
    Nanus, David M.
    Bander, Neil H.
    CANCER RESEARCH, 2012, 72
  • [35] Phase I trial of fractionated-dose 177lutetium radiolabeled anti-specific membrane antigen (PSMA) monocional antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Oshorne, J.
    Goldsmith, S. J.
    Petrillo, K.
    Tyrell, L.
    Dhillon, G. S.
    Beltran, H.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
1234